Evidence map›Paper›PMID 35912166›Full record

ArticleFrontiers in oncology2022

Highly Invasive Fluorescent/Bioluminescent Patient-Derived Orthotopic Model of Glioblastoma in Mice.

Diana Yuzhakova, Elena Kiseleva, Marina Shirmanova, Vladislav Shcheslavskiy, Daria Sachkova, Ludmila Snopova, Evgeniya Bederina, Maria Lukina, Varvara Dudenkova, Gaukhar Yusubalieva and 3 more

Erratum issuedOpen access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
5.0field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Efficacy Evaluation of "Enhanced" Natural Killers withSovremennye tekhnologii v meditsine · 2025
    Article
  8. Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 2 countries.

Diana YuzhakovaInstitute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.
Elena KiselevaInstitute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.
Marina ShirmanovaInstitute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.
Vladislav ShcheslavskiyInstitute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.
Daria SachkovaInstitute of Biology and Biomedicine, Lobachevsky State University of Nizhny Novgorod, Nizhny Novgorod, Russia.
Ludmila SnopovaInstitute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.
Evgeniya BederinaInstitute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.
Maria LukinaLaboratory of Molecular Oncology, Federal Research and Clinical Center of Physical and Chemical Medicine, Moscow, Russia.
Varvara DudenkovaInstitute of Experimental Oncology and Biomedical Technologies, Privolzhsky Research Medical University, Nizhny Novgorod, Russia.
Gaukhar YusubalievaBiomedical Research Center, Federal Research and Clinical Center, Federal Medical and Biological Agency, Moscow, Russia.
Tatyana BelovezhetsDepartment of Molecular Immunology, Institute of Molecular and Cellular Biology SB RAS, Novosibirsk, Russia.
Daria MatvienkoDepartment of Molecular Immunology, Institute of Molecular and Cellular Biology SB RAS, Novosibirsk, Russia.
Vladimir BaklaushevBiomedical Research Center, Federal Research and Clinical Center, Federal Medical and Biological Agency, Moscow, Russia.
Privolzhsky Research Medical University · RUInstitute of Molecular and Cell Biology · RUBecker Technologies (Germany) · DEEngelhardt Institute of Molecular Biology · RUFederal Medical-Biological Agency · RUN. I. Lobachevsky State University of Nizhny Novgorod · RUResearch Institute of Physical Chemical Medicine · RU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Development of the novel diagnostic and therapeutic approaches in neuro-oncology requires tumor models that closely reproduce the biological features of patients' tumors. Patient-derived xenografts (PDXs) are recognized as a valuable and the most "close-to-patient" tool for preclinical studies. However, their establishment is complicated by the factors related to both the surgical material and technique of the orthotopic implantation. The aim of this work was to develop a patient-derived glioblastoma multiform (GBM) model that stably co-expresses luciferase and a far-red fluorescent protein for monitoring of tumor progression in the brain and, using this model, to validate new diagnostic methods-macroscopic fluorescence lifetime imaging (macro-FLIM) and cross-polarization optical coherence tomography (CP OCT). The established model was similar to the original patient's GBM in terms of histological and immunohistochemical features and possessed reproducible growth in nude mice, which could be observed by both fluorescence and bioluminescence imaging. Our results demonstrated the high potential of macro-FLIM and CP OCT for intraoperative differentiation of GBM from the white matter. Thus, the dual-labeled PDX model of GBM proved to be an excellent approach for observation of tumor development by optical methods.

Indexed as

FLIM (fluorescence lifetime imaging microscopy)fluorescence imagingglioblastoma (GBM)patient-derived xenograft (PDX)primary cell line

Identifiers

PMID35912166
PMCPMC9326400
OpenAlexW4285087414

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.